A cute liver failure (ALF) affects over 2000 Americans per year and results in approximately 400 liver transplants annually. Defined as the abrupt loss of hepatocellular function in patients with previously normal liver function, the most common etiologies are acetaminophen overexposure and acute viral hepatitis. 1 In the most severe cases, patients manifest a rapidly developing coagulopathy, and encephalopathy that progresses to cerebral herniation and death without prompt liver transplantation. 2 Fewer than half of patients with ALF will spontaneously recover with supportive care alone, yet at present, no pharmacologic or adjunct therapies have been shown to be of benefit in this clinical scenario. For these critically ill patients, liver transplantation frequently represents the only option for survival; however, this limited resource may be inaccessible at the time at which it is emergently needed. Furthermore, the decision to proceed to transplantation is not always straightforward, because some patients will spontaneously recover but the ability to predict recovery is markedly limited. Under aggressive utilization of liver transplantation can result in devastating outcomes in potentially salvageable patients, whereas overly aggressive utilization of transplantation both commits patients who might have spontaneously recovered to a lifetime of immunosuppression, and also unnecessarily uses precious grafts that could be allocated to others in need. New therapies, particularly those that can promote spontaneous recovery and lessen the need for liver transplantation, are badly needed.
Mechanisms of hepatic regeneration after liver injury are well understood: mitotic division of mature hepatocytes promptly regenerates liver mass and function in sublethal settings. 3 When this mechanism is blocked or is inadequate, circulating bone marrowderived hematopoietic stem cells (HSCs) participate in liver injury recovery. 4 Circulating HSCs are characterized by the cell surface marker CD34: a glycoprotein involved in cell-cell adhesion interactions that is also expressed on cells in the umbilical cord, mesenchymal stem cells, endothelial progenitor cells, and on mature endothelial cells. 5 It has recently been reported that levels of CD34 ϩ HSCs are increased in the peripheral circulation of patients after liver resection, 6 though the magnitude of the increase has not been demonstrated in other studies. 7 Certainly, although innate mechanisms that lead to stem cell mobilization may contribute to liver repair in some circumstances, this mechanism is inadequate in the setting of severe liver injury.
Pharmacologic mobilization of HSCs has emerged as the standard of care for patients with hematologic malignancies that require autologous bone marrow transplantation after ablative chemotherapy. 8 Currently, patients with non-Hodgkin lymphoma or multiple myeloma are treated with autologous stem cell transplant undergo HSC mobilization with granulocyte colony-stimulating factor (G-CSF), (Neupogen, Amgen) and plerixafor (Mozobil, Genzyme) for 5 days prior to plasmapheresis and cell collection. 9 This preparatory regimen results in a synergistic mobilization of large numbers of CD34 ϩ stem cells via antagonism of the CXCR4-stromal-derived factor (SDF-1) interaction, which anchors stem cells to their home in the bone marrow. 10 HSC mobilization protocols have thus been developed and optimized in the autologous bone marrow transplantation setting but have not yet been considered for treatment of acute liver injury, where they may be of benefit. Any pharmacologic intervention which improved outcomes in this difficult patient population by increasing the chance of spontaneous liver recovery, especially one that uses medicines already known to be safe and in current clinical use, would be of great benefit. We describe herein the use of stem cell mobilization to improve survival in an animal model of ALF.
METHODS

Rodent Models of ALF
Female Lewis rats or C57BL/6 mice were administered various doses of carbon tetrachloride (CCl 4 , Sigma) via intraperitoneal injection to determine the sublethal dose that would best recapitulate ALF in humans. CCl 4 was dissolved in mineral oil to a final of concentration of 50% for mice and 25% for rats, and was administered by single intraperitoneal injection at doses ranging from 2 mL/kg to 4.5 mL/kg under inhaled isoflurane anesthesia. To account for the inherent variability in survival and severity of injury after CCl 4 injection, each treatment group was comprised of 8 to 10 animals. For characterization of hepatic injury in response to CCl 4 injection, animals were killed daily for measurement of serum transaminases (aspartate transaminase (AST) and ALT), and for histopathologic analysis of liver injury. All experimental regimens were repeated for survival analyses, and animals were observed for up to 16 days.
All animals were housed in an approved microisolation facility with free access to food and water in a light-cycled room. All experimental protocols were approved by the Johns Hopkins University Institutional Animal Care and Use Committee.
Mobilization of HSCs
For HSC mobilization, plerixafor and G-CSF were administered by subcutaneous injection at weight-based doses consistent with those that have proven effective in human clinical trials or as has been used in our laboratory previously (plerixafor, 2 mg/kg/ dose; G-CSF 300 g/kg/dose). Plerixafor and G-CSF were administered 12-hour following CCl 4 injection, in treatment groups comprised of 8 to 10 animals. Control treatment groups were administered an injection with an equivalent volume of saline.
Flow Cytometric Analysis of Peripheral Blood
Following HSC mobilization, animals were killed at either 1 or 6 hours post-treatment, and blood was collected. Leukocyte suspensions (1 ϫ 10 6 ) of peripheral blood were analyzed for CD34, Thy-1, and c-Kit expression. Nonspecific antibody binding was blocked with mouse and donkey serum (Sigma) for 30 minutes. The cells were incubated with Alexa Fluor 647 conjugated mouse antirat CD34 (1:10, Santa Cruz biotechnology), fluorescein isothiocyanate-conjugated mouse anti-rat CD90 (Thy-1, 1:100, BD Pharmingen), and rabbit anti-rat c-Kit (1:100, Santa Cruz biotechnology) for 45 minutes at 4°C, and followed by phycoerythrin-conjugated donkey anti-rabbit IgG (1:200, eBioscience) for 30 minutes at 4°C. The CD34, Thy-1, and c-Kit positive cells were counted by flow cytometry (fluorescence-activated cell sorting), using CELLQuest software (Becton-Dickinson).
Histology and Immunohistochemistry
Frozen sections of 5 m cut serially were fixed with acetone at Ϫ20°C for 10 minutes and dried for 1 hour at room temperature. The streptavidin-biotin-peroxidase method with the DAKO Kit (Carpinteria, CA) was used to detect CD34 antigen. After the blocking of nonspecific binding of antibody, the specimens were reacted with goat anti-CD34 (1:100; R&D Systems, Inc.) at 4°C overnight. Subsequently, the sections were incubated with Biotin-SP-conjugated bovine anti-goat IgG (1:200, Jackson Laboratory) at room temperature for 30 minutes. Diaminobenzidine tetrahydrochloride was used as the chromogen, and hematoxylin was used for counterstaining.
RESULTS
CCl 4 Administration Recapitulates ALF in Rodents
Animals that were treated with increasing amounts of CCl 4 showed a dose-dependent decrement in survival (Fig. 1A) . Groups of 10 animals that were treated with 2 mL/kg routinely showed 1 or 2 mortalities per 10 within the first 1 to 2 days after treatment. A majority of animals in this group were transiently ill, but rapidly regained vigor. Animals that received 3 mL/kg showed higher mortality rates, typically 3 or 4 animals died but reliably more than half recovered spontaneously. A dose of 4 mL/kg would result in 60% to 100% mortality among the animals over the course of 3 to 7 days. Slight adjustments in the dose (ie, 4.5 mL/kg) at this level would have obvious effects in mortality with all animals succumbing within 24 to 48 hours. A dose of 4 mL/kg was eventually selected for the final model. Mortality with this dose was typically 80% around 5 days and was preceded by a significant elevation in serum transaminases. AST and ALT levels peaked at approximately 5000 on day 1 to 2 after injury (Fig. 1B) . Histologic examination of rodent livers after injury revealed marked inflammation and necrosis which increased over the first 3 days (Fig. 1C) . Injured livers displayed penetrating inflammatory cells and increased hepatocyte vacuolization as well as apoptotic bodies consistent with severe injury.
There was low but persistent variability between groups of animals and batches of CCl 4 based on baseline animal vigor at time of delivery to our institution, strength of drug, and efficacy of delivery by injection.
Plerixafor and G-CSF Mobilize a Population of CD34؉ HSCs in Rodent
Rats that received either plerixafor or G-CSF showed an increase in their peripheral white blood cell (WBC) counts at 1 and 6 hours ( Fig. 2A) . Animals receiving plerixafor alone had an average total WBC of 6100 at 1 hour (n ϭ 3) and 7300 at 6 hours (n ϭ 3). Animals receiving G-CSF alone had average total WBCs of 3300 at 1 hour (n ϭ 3) and 7800 at 6 hours (n ϭ 3). Animals receiving both drugs had an average total WBC count of 6000 at 1 hour (n ϭ 3) and of 9900 at 6 hours (n ϭ 3). The lymphocyte compartment, which is thought to contain the majority of HSCs showed similar changes ( Fig. 2A) . Animals receiving plerixafor had total lymphocyte counts of 4400 and 4800 at 1 and 6 hours, respectively. Animals receiving G-CSF had total lymphocyte counts of 2000 and 4100 at 1 and 6 hours, respectively. Animals receiving both drugs had total lymphocyte counts of 3600 and 5200 at 1 and 6 hours, respectively. CD34ϩ cells were increased in all 3 treatment groups (Fig. 2B) . Animals that received plerixafor alone had peripheral CD34ϩ absolute counts of 333 and 135 cells/mL at 1 and 6 hours, respectively. Animals that received G-CSF alone had absolute CD34ϩ cell totals of 216 and 238 at 1 and 6 hours. Animals that received both drugs had peripheral CD34ϩ cells counts of 363 and 346 cells/mL. Though rats have a wider distribution of "normal" starting peripheral WBC counts, the mobilization results shown closely mirrors that known to occur after administration of these agents in humans whom likewise show a robust increase at 6 hours ( Fig. 2C) , which peaks at 9 hours. 11 Administration of both agents together resulted in the greatest increase in serum WBCs. Analysis of the mobilized population showed it to be enriched with CD34ϩ HSCs (Fig. 2B) with the greatest absolute CD34ϩ numbers in the serum of animals treated with both plerixafor and G-CSF. This response is similar to that seen in humans after administration of plerixafor and G-CSF.
Stem Cell Mobilization Improves Survival in an Animal Model of ALF
Rodents (n ϭ 8) that were administered intraperitoneal CCl 4 (4 mL/kg) displayed a high rate of mortality (75% at 6 -7 days) consistent with our model. In contrast, animals (n ϭ 8) that received an identical injury (4 mL/kg) but 12 hours later initiated plerixafor (2 mg/kg/d ϫ 3 days) and G-CSF (300 g/kg/d ϫ 3 days) survived 
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Stem Cell Mobilization in Liver Failure at a much higher rate (13% mortality) (Fig. 3A) . Examination of liver specimens from intentionally killed animals from the treated and untreated groups after injury showed lesser histologic injury in the group that had received stem cell mobilization (Fig. 3B ).
Animals That Have Undergone Stem Cell Mobilization After Liver Injury Show CD34؉ HSCs Infiltrating Their Livers
Animals that underwent CCl 4 injury (or control vehicle) and stem cell mobilization (or control saline injection) were killed at days 1 or 3 and underwent hepatectomy. Thin slide microscopy after staining with antibodies specific for CD34 revealed the presence of significant periportal infiltrating HSCs at 24 hours (Fig. 4A, 4) . Conversely, animals that had undergone injury only (Fig. 4A, 3) , or had been treated with mobilizing agents but no injury (Fig. 4A, 2 ) displayed far fewer CD34ϩ cells in hepatectomy specimens. Animals that received neither injury nor stem cell mobilization showed no CD34ϩ staining at 24 hours (Fig. 4A, 1) . Panel 4B shows increased CD34 staining over 5 days in animals that were injured and underwent stem cell mobilization.
DISCUSSION
Patients with ALF represent a challenging group. Untreated, they have high mortality rates, though if they survive they will return to normal functioning spontaneously. There is a life-saving therapy available, but it is a resource badly needed by others who have no hope of spontaneous recovery and survival rates after transplant for ALF are known to be far inferior to that of liver transplant for other indications. 12 ALF patients are often critically ill, and decisions must be made rapidly. Novel medical therapies that improve the rate of spontaneous recovery in these patients would be extraordinarily helpful.
Why the liver fails to use all possible recovery pathways, ie, recruitment of endogenous marrow-derived stem cells, in these scenarios of massive insult is unclear. It has been shown that G-CSF can be given safely and effectively to patients with chronic liver disease and that CD34ϩ HSCs can be mobilized effectively in this population. [13] [14] [15] Further, it has been shown that patients with ALF have markedly lower serum levels of several stem cell mobilizing factors, like SCF (stem cell factor) and thrombopoietin. Interestingly, levels were lowest in the group of ALF patients who had the worst eventual outcomes. 16 Augmenting the release of marrowbound stem cells has been well studied and optimized for utilization in a very different group of patients who donate via pheresis for subsequent HSC autotransplantation after chemoablation of their lymphoma or myeloma. Meanwhile, efforts to augment liver recovery from injury with stem cells has thus far focused on provision of exogenous stem cells with success demonstrable in some animal models. 17 In this article, we have combined these lines of inquiry and use pharmacologic mobilization of endogenous HSCs in the setting of liver injury to show that these cells can be of therapeutic benefit. Our model shows survival advantage from the treatment provided but the mechanism of benefit remains undescribed. We have demonstrated an elevation of serum leukocytes and CD34ϩ cells in animals treated with plerixafor and G-CSF, and it is the mobilization of these HSCs that are key in the current oncologic uses of these drugs, though it is recognized that CD34 is an imperfect surrogate for the cell population that mediates recapitulation of the marrow after ablative chemotherapy. We have also shown in the present article the rapid appearance of CD34ϩ cells in the livers of only the animals who undergo injury and stem cell mobilization, again suggesting a role for these cells in the treatment benefit but not necessarily a mechanism. These cells could conceivably differentiate into hepatocytes to directly support an animal with inadequate liver mass or perhaps supply some sort of paracrine support to mitigate injury or accelerate ongoing local repair mechanisms. Though the mechanism by which HSCs exert their benefit in this model remains undetermined, we are undertaking experiments that will discriminate between an effect that lessens injury versus one that promotes recovery. Experiments that carefully assess levels of injury to the liver using CCl 4 as well as other toxins like acetaminophen preliminarily show similar injury profiles in animals treated with stem cell mobilizing agents versus control animals suggesting a mechanism involving primarily enhancement of injury recovery (unpublished data).
Plerixafor was initially studied as an anti-human immunodeficiency virus (HIV) drug as it was found to be a small molecule antagonist of CXCR4, then known as an HIV coreceptor.
18 CXCR4 also binds stromal-derived factor 1 (SDF-1) and this interaction anchors HSCs to their niche in the bone marrow. Elevated levels of SDF elsewhere in the body, ie, at the site of injured tissue, create a gradient that releases stem cells from the marrow, perhaps so that they may participate in tissue repair elsewhere in the body. Why this process is not more efficient in settings like massive liver injury is unclear. Plerixafor was not an effective anti-HIV agent in vivo but resulted in massive mobilization of HSCs to the periphery when given to healthy volunteers. Plerixafor acts synergistically with G-CSF in mobilizing HSCs in clinical trials as well as in our animals, and thus allows for assessment of whether endogenous stem cells are able to participate in tissue repair under optimized conditions, whatever their exact role may be. To be clinically relevant in scenarios of ALF, stem cell mobilizing agents would have to exert their beneficial effect on survival even when given well after injury has been detected. We are currently performing experiments to test how long treatment with G-CSF and plerixafor can be delayed after initial injury and still result in survival improvement. Plerixafor is also known to mobilize a more diverse population from the marrow beyond CD34ϩ cells. Whether its other actions may be mediating the benefit seen here remains to be clarified and is the subject of ongoing research in our laboratory and others.
Effective pharmacologic mobilization of marrow-derived stem cells to liver may have application in other settings as well. Quicker recovery after surgical resection or larger surgical resections could be facilitated, for example. Transplant applications might include the ability to use ever more extended criteria grafts, or ever smaller living donor grafts, which would then serve as scaffolds for endogenous repopulation by mobilized host stem cells. Perhaps this pharmacologically driven graft repopulation by recipient cells might lead to an eventual conversion of the donor graft to recipient phenotype creating a novel type of "tolerance" protocol, a phenomenon described in animal models previously. 19 Applications with other tissues in other injury scenarios are possible as well. Benefit has already been reported from treatment with G-CSF after myocardial infarction and with acute kidney injury. 20 -22 Clinical familiarity with G-CSF and plerixafor and their relatively benign side effect profiles make these protocols immediately attractive, especially for this challenging group of ALF patients that has few other options, suggesting the need for a clinical trial if results can first be repeated in a large animal preclinical model of liver injury.
DR. DAVID GELLER (PITTSBURGH, PENNSYLVANIA): Whereas carbon tetrachloride is a model for both acute and chronic liver injury, I think it would be important before moving to clinical trial to consider other animal models of ALF to see whether this is reproducible. In rodents, for example, thioacetamide or galactosamine, and certainly it would be important to test this strategy in a large animal model before considering a clinical trial in humans. My second question is in regards to the mechanism. Your article is noticeably scant on data for the mechanism of action. Although the CD34 stem cell is an interesting hypothesis, there are no data shown yet to prove a cause and effect relationship. Have you looked at some of the more conventional liver regenerative factors, such as hepatocyte growth factor, transforming growth factor ␣, or epidermal growth factor, and also the interleukin-6/Stat3 pathways? DR. CHARLES J. YEO (PHILADELPHIA, PENNSYLVANIA): This is not my area of expertise per se, but I do have 3 quick questions for you. First, it would seem that a converse experiment you could perform would be to try to somehow ablate bone marrow progenitor cells and see if, in so doing, in your model such ablation would lead to an adverse outcome. Have you tried this?
Number 2, getting back to David Geller's question about mechanism, you showed the effects in the liver with the CD34 cells upregulated and migrating to the area. How about looking at the effects on other organs, and looking at circulating metabolic toxins, their level. Do they have any effect on the ultimate outcome?
Last, there are other drugs that more specifically stimulate bone marrow progenitor cells. Have you looked at more specific stimulants of bone marrow cells to try to specify what cells are truly responsible for your positive effect? DR. RAINER GRUESSNER (TUCSON, ARIZONA): The main clinical issue is that ALF can progress very quickly; it can ultimately result in hepatic encephalopathy with severe brain edema or even brain death.
First, how many additional CD34 cells were mobilized in your model within a short period, i.e., within the first 12 to 24 hours? Second, if you are able to mobilize these stem cells within a short period, can you speculate about their impact on hepatic encephalopathy or about the mechanism(s) for its reversal? If the lag time to mobilize these stem cells is short, you may have a novel clinical approach to this frequently fatal condition. DR. ANDREW CAMERON (BALTIMORE, MARYLAND): Dr. Brayman, your first question asked whether we ever gave our treatment drugs later than 12 hours after the initial carbon tetrachloride injury. This is an important question, as we often see our ALF patients transferred from another hospital days after their Tylenol ingestion.
Our initial animal model was designed to yield mortality within 3 to 7 days, but we observed that animals occasionally died within 24 hours. So, in our earliest experiments, we waited only for 12 hours, some animals die, and had no treatment window. We could certainly lower our injury dose slightly and try delayed treatment to look for benefit in that scenario as well. I think that leads to your second question, about the role of stem cells in chronic end-stage liver disease. I am pessimistic about this application, as the fibrosis and resultant portal hypertension are the real problems in these scenarios, as opposed to parenchymal insufficiency.
However, your suggestion of examining other acute injury scenarios, especially acute pancreatitis, I think is important. Patients with acute pancreatitis, like those with ALF, are often critically ill, and do not have good medical therapy options. The rat model is most frequently used for acute pancreatitis. There is an excellent animal model, utilizing hypercalcemia, with much of the work coming from Dr. Warshaw's group at the Massachusetts General Hospital in the 90s. I think those animals could be challenged with stem cell mobilizing agents.
Dr. Geller asked about other mechanisms. In our laboratory, we currently use 3 models to generate ALF. One is carbon tetrachloride, another is acetaminophen toxicity, and the other is 90% hepatectomy. We have seen benefit in preliminary experiments in each of these models. The mechanism questions are critically important, and we are embarking on the molecular characterization of our survival phenomenon, only the earliest of which were described in our current study.
I think, the big picture mechanistic question is whether plerixafor and granulocyte colony-stimulating factor are mobilizing marrow-derived stem cells that help the liver recover, or are they lowering the extent of liver injury that occurs. It will be relatively easy to answer that question first, before we characterize, say, the cell population that is involved.
Dr. Yeo, we have not tried to avoid stem cell mobilization to abrogate our survival effect. That is a very good idea, and I think, again, the question is raised about what plerixafor does specifically.
Let me conclude by addressing Dr. Gruessner questions. The important question of whether stem cell therapy may require too much lag time to help patients with ALF. We did try to create a model in which animals died relatively soon after injury to recreate the urgency that humans with ALF are facing, but you are correct, any therapy, stem cell, or otherwise, must work quickly to be relevant. These drugs seem to fulfill that criterion, but clearly, in the actual care of a patient with liver failure, if the patient did not improve with treatment or if the injury was simply too massive for spontaneous recovery, it would be essential to forgo any notion of medical therapy and proceed immediately with life-saving liver transplantation.
I think stem cell therapy, if it works, would not help those who are too far gone, nor would it be necessary for those who are clearly already recovering, but it may impact on that very difficult group in the middle.
